KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Liabilities from Discontinued Operations (2018 - 2023)

Historic Liabilities from Discontinued Operations for Novartis Ag (NVS) over the last 5 years, with Q3 2023 value amounting to $8.8 billion.

  • Novartis Ag's Liabilities from Discontinued Operations changed N/A to $8.8 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $8.8 billion, marking a year-over-year change of. This contributed to the annual value of $31.0 million for FY2019, which is 3921.57% down from last year.
  • According to the latest figures from Q3 2023, Novartis Ag's Liabilities from Discontinued Operations is $8.8 billion.
  • In the past 5 years, Novartis Ag's Liabilities from Discontinued Operations registered a high of $8.8 billion during Q3 2023, and its lowest value of $24.0 million during Q3 2019.